Johnson & Johnson’s COVID-19 vaccine candidate generated an immune response in nearly all clinical trial volunteers after a single dose, according to interim data analysis published Jan. 13.
Johnson & Johnson is falling behind on its original promise to deliver 100 million doses of its COVID-19 vaccine candidate by the end of June.
Pfizer notified national governments across the globe that it will deliver fewer doses than usual of its COVID-19 vaccine until mid-February as it renovates one of its factories in Puurs, Belgium.
Horsham, Pa.-based Institute for Safe Medication Practices released three main errors being reported regarding the COVID-19 vaccination process: dilution, mix-ups with similar products and wasted doses.
California’s state epidemiologist, Erica Pan, MD, told healthcare providers Jan. 17 to stop using a batch of Moderna’s COVID-19 vaccine after a “higher than usual” number of severe allergic reactions took place at a vaccination clinic in San Diego.
More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.